Clinical Trial Update: Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating azacitidine, lenalidomide, and donor lymphocyte infusion as salvage therapy for relapsed diseases after allogeneic stem cell t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Donor Lymphocyte Infusion
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED